NCT05132582 2026-04-07
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT03975647 2026-03-30
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT05323955 2026-03-17
BRIDGET
Duke University
Phase 2 Active not recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT05382364 2026-03-12
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
Phase 1 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT05892068 2026-02-13
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04721977 2026-01-09
MK-7119-001
Pfizer
Phase 2 Active not recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT05041842 2025-11-17
InTTercePT
UNICANCER
Phase 2 Active not recruiting
NCT04457596 2025-10-29
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT05190445 2022-09-08
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Pieris Pharmaceuticals, Inc.
Phase 2 Active not recruiting